Pharmacokinetics/Pharmacodynamics/Pharmacogenomics PRN Focus Session — When Genotyping Isn’t Enough: Rare Genetic Variants and Real-Life Influences on Medication Response

Pharmacogenomic testing has transformed personalized medicine, but real-world challenges often extend beyond genetic analysis. Rare genetic variants, incomplete evidence, and complex clinical scenarios can lead to unexpected drug responses, even when guidelines are followed. This 90-minute session will consist of the following two 40-minute presentations (including 5 minutes at the end of each session for a question-and-answer session) that explore distinct critical dimensions of precision medicine, with each presentation beginning with a patient case to illustrate the importance of the topic to ACCP’s 2026 theme of patient safety and avoiding patient harm. The first presentation will focus on recent progress in the routine clinical uptake of DPYD genotyping to guide fluoropyrimidine chemotherapy use and caveats for use. The second presentation will discuss non-genetic factors -- such as drug interactions, organ function, and environmental influences-- that are known to alter drug disposition phenotypes. Through case-based discussion and evidence review, attendees will learn strategies to navigate these complexities and optimize patient care. By addressing gaps between genotype and clinical reality, this session aims to equip pharmacists with practical tools for individualized therapy.

DPYD: From Evidence to Advocacy to Action 3:30 p.m. to 4:15 p.m. Speaker: D. Max Smith, III, Pharm.D., BCPS

Your Patient is More Than a Genotype: Non-Genetic Factors That Impact Phenotype 4:15 p.m. to 5:00 p.m. Speaker: Cyrine E. Haidar, Pharm.D., BCOP St. Jude Children’s Hospital, Memphis, Tennessee